AMRI, Medicinal Chemistry Department, 30 Corporate Circle, PO Box 15098, Albany, NY 12212, USA.
Bioorg Med Chem Lett. 2011 Jan 1;21(1):324-8. doi: 10.1016/j.bmcl.2010.11.006. Epub 2010 Nov 5.
A series of novel hydroxamic acid based histone deacetylases (HDAC) inhibitors with aryl ether and aryl sulfone residues at the terminus of a substituted, unsaturated 5-carbon spacer moiety have been synthesized for the first time and evaluated. Compounds with meta- and para-substitution on the aryl ring of ether hydroxamic acids 19c, 20c, 19e, 19f and 19g are potent HDAC inhibitors with activities at low nanomolar levels.
首次合成并评估了一系列新型的基于羟肟酸的组蛋白去乙酰化酶(HDAC)抑制剂,其在取代的、不饱和的 5 碳间隔基的末端具有芳基醚和芳基砜残基。具有醚羟肟酸 19c、20c、19e、19f 和 19g 芳环上间位和对位取代的化合物是具有低纳摩尔水平活性的强效 HDAC 抑制剂。